Margaret Flynn is still waiting for a lung transplant. Now, the Ladysmith resident has been on the current waiting list longer than anyone else. “It’s a rare match,” said Flynn, who has O negative blood as well as certain anti bodies in the blood, making her difficult to match to...
Latest News
CARY, N.C. — Focal Medical, Inc., a privately held biopharmaceutical company developing a targeted therapeutic system to treat inoperable tumors and to deliver genomic medicines, today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application to initiate a Phase 1b clinical trial of ACT-IOP-003,...
A 31-year-old man from Bratton has organised his first event as part of a five-year campaign to help a specialist school raise £2.4m for a hydro swimming pool and early learning centre. Radek Evans, 31, from Carpenters Lane,who has previously raised money for Hope Nature Centre in Southwick, and Dorothy...
ROME, Italy — Fondazione Telethon announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Waskyra, an ex vivo gene therapy for patients with Wiskott-Aldrich syndrome (WAS), a rare and life-threatening immunodeficiency. WAS, seen almost exclusively in males, affects blood cells and cells of the immune system (the body’s...
Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy could become the new standard of care, according to a new City of Hope study. LOS ANGELES, Calif. — A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic...
NEW YORK, NY — Immunotherapy has been disappointing as a prostate cancer treatment, but a new Columbia study suggests that the powerful treatments have potential when the disease starts to spread. The study, published in Cancer Cell, found that metastatic prostate tumors contain a rich variety of immune cells that can...
TAIPEI — Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) today announces that the first patient has been dosed in the Casppian Phase 3 registration study. “The Casppian Phase 3 study is an open-label, multicenter clinical trial to evaluate the efficacy, safety, and pharmacokinetics of leuprolide (FP-001) 42 mg-controlled release in patients with...
TAIPEI, Taiwan — Foresee Pharmaceuticals (TPEx: 6576), announced the positive safety review by the independent Data and Safety Monitoring Board for its Casppian Phase 3 registration study. The DSMB recommended that Foresee Pharmaceuticals continue the trial with a minor amended protocol. The Casppian Phase 3 study is an open-label, multicenter,...
TAIPEI— Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) announced today that the company will be presenting at the American Heart Association (AHA) 2023 Annual Meeting taking place in Philadelphia, PA, from November 11-13, 2023. The presentation will focus on Foresee’s first-in-class oral ALDH2 activator, FP-045, and the clinical design of Phase 2...
COLUMBUS, Ohio — Forge Biologics (Forge), a member of Ajinomoto Bio-Pharma Services and a leading manufacturer of genetic medicines, announced a clinical update today on five patients with Krabbe disease that have received FBX-101, an AAV gene therapy, after hematopoietic stem cell transplantation (HSCT). Timothy J. Miller, Ph.D., CEO and...